Prothena Corporation plc - Ordinary Shares (PRTA): Price and Financial Metrics

Prothena Corporation plc - Ordinary Shares (PRTA): $48.20

-3.28 (-6.37%)

POWR Rating

Component Grades













Add PRTA to Watchlist
Sign Up

Industry: Biotech


of 496

in industry


  • PRTA scores best on the Growth dimension, with a Growth rank ahead of 73.5% of US stocks.
  • The strongest trend for PRTA is in Momentum, which has been heading down over the past 31 weeks.
  • PRTA ranks lowest in Momentum; there it ranks in the 5th percentile.

PRTA Stock Summary

  • Prothena Corp Public Ltd Co's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 7.96% of US listed stocks.
  • PRTA's price/sales ratio is 2,631.8; that's higher than the P/S ratio of 99.56% of US stocks.
  • The volatility of Prothena Corp Public Ltd Co's share price is greater than that of 97.94% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Prothena Corp Public Ltd Co are FENC, ATOM, CKPT, SRRA, and VBIV.
  • Visit PRTA's SEC page to see the company's official filings. To visit the company's web site, go to

PRTA Valuation Summary

  • PRTA's price/sales ratio is 2631.8; this is 22109.28% higher than that of the median Healthcare stock.
  • PRTA's price/earnings ratio has moved down 14.2 over the prior 105 months.
  • Over the past 105 months, PRTA's price/earnings ratio has gone down 14.2.

Below are key valuation metrics over time for PRTA.

Stock Date P/S P/B P/E EV/EBIT
PRTA 2020-03-04 560.0 1.7 -5.9 -1.3
PRTA 2019-12-04 654.1 1.7 -6.3 -1.6
PRTA 2019-04-26 454.1 1.3 -2.8 0.0
PRTA 2017-11-17 72.7 4.5 -12.9 -9.7
PRTA 2016-07-21 1432.8 3.9 -19.7 -14.7
PRTA 2016-03-10 719.2 3.2 -14.3 -9.8

PRTA Growth Metrics

  • Its 2 year net cashflow from operations growth rate is now at 53.01%.
  • Its 5 year net income to common stockholders growth rate is now at -15.55%.
  • The 3 year revenue growth rate now stands at -28.54%.
Over the past 34 months, PRTA's revenue has gone down $82,000.

The table below shows PRTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 0.872 -90.861 -124.31
2020-12-31 0.853 -80.362 -111.144
2020-09-30 0.749 -75.756 -101.982
2020-06-30 0.797 -65.295 -90.853
2020-03-31 0.769 -58.701 -80.381
2019-12-31 0.814 -52.969 -77.677

PRTA Price Target

For more insight on analysts targets of PRTA, see our PRTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.40 Average Broker Recommendation 1.79 (Moderate Buy)

PRTA Stock Price Chart Interactive Chart >

Price chart for PRTA

PRTA Price/Volume Stats

Current price $48.20 52-week high $67.08
Prev. close $51.48 52-week low $9.67
Day low $45.09 Volume 440,400
Day high $50.54 Avg. volume 463,864
50-day MA $43.33 Dividend yield N/A
200-day MA $23.78 Market Cap 2.13B

Prothena Corporation plc - Ordinary Shares (PRTA) Company Bio

Prothena Corporation plc is a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel protein immunotherapy programs for the potential treatment of diseases that involve amyloid or cell adhesion. The company was founded in 2012 and is based in Dublin, Ireland.

PRTA Latest News Stream

Event/Time News Detail
Loading, please wait...

PRTA Latest Social Stream

Loading social stream, please wait...

View Full PRTA Social Stream

Latest PRTA News From Around the Web

Below are the latest news stories about Prothena Corp Public Ltd Co that investors may wish to consider to help them evaluate PRTA as an investment opportunity.

Is Prothena Corporation plc (PRTA) A Good Stock To Buy?

The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

Yahoo | July 26, 2021

Prothena Presents New Data from Robust Alzheimer’s Portfolio at the Alzheimer’s Association International Conference 2021

Late-breaking PRX012 poster highlights significant ex vivo clearance of both pyroglutamate-modified and -unmodified Aβ plaque from AD brain at concentrations expected to be reached in CNS with subcutaneous administrationPoster presentation demonstrates dual Aβ-tau vaccines simultaneously generate antibodies that neutralize and clear pathogenic Aβ and block pathogenic tau interaction DUBLIN, Ireland, July 26, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical c

Yahoo | July 26, 2021

Prothena to Present Data from Two of its Alzheimer’s Disease Programs at the Alzheimer’s Association International Conference 2021

DUBLIN, Ireland, July 20, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that it will present preclinical data on two of its Alzheimer’s disease (AD) programs at the Alzheimer’s Association International Conference® 2021 (AAIC®), to be held online and in-person July 26-30, 2021. The two presentations will focus on data for PRX012,

Yahoo | July 20, 2021

Got $2,500? Check Out These 3 Alzheimer's Therapy Stocks

Treating Alzheimer's is extremely difficult, but these innovative companies are taking a stab at it.

Yahoo | July 17, 2021

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Yahoo | July 16, 2021

Read More 'PRTA' Stories Here

PRTA Price Returns

1-mo -1.09%
3-mo 79.52%
6-mo 329.97%
1-year 282.54%
3-year 223.71%
5-year -12.44%
YTD 301.33%
2020 -24.13%
2019 53.69%
2018 -72.53%
2017 -23.79%
2016 -27.78%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9025 seconds.